Nuvectis Pharma, Inc. (NVCT)

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet